浩欧博股价涨5.1%，诺安基金旗下1只基金重仓，持有1.71万股浮盈赚取14.07万元

Group 1 - The core point of the news is that Jiangsu Haobo Bio-Pharmaceutical Co., Ltd. has seen a stock price increase of 5.1%, reaching 169.21 yuan per share, with a total market capitalization of 10.741 billion yuan [1] - The company, established on June 8, 2009, specializes in the research, production, and sales of in vitro diagnostic reagents, with reagent sales accounting for 89.46% of its main business revenue [1] - Other revenue sources include sales from other products at 5.86%, instrument sales at 3.84%, and rental sales at 0.85% [1] Group 2 - From the perspective of major fund holdings, one fund under Nuoan Fund has heavily invested in Haobo, with Nuoan Jingxin Mixed Fund holding 17,100 shares, representing 5.9% of the fund's net value [2] - The fund has achieved a year-to-date return of 51% and a one-year return of 57.74%, ranking 453 out of 8,026 in its category [2] - The fund manager, Li Yuliang, has a tenure of over 10 years, with the best fund return during his management being 193.95% [2]